Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Rang in Aktien #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Aktienkurs
$19.30
Zuletzt synchronisiert: 2023-12-26
Marktkapitalisierung
$72.77M
Veränderung (1 Tag)
6.22%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Aeglea BioTherapeutics, Inc. (AGLE)

Kategorie

Kursverlauf für Aeglea BioTherapeutics, Inc. (AGLE)
Höchster Schlusskurs: $17.81 am 2023-12-01

Niedrigster Schlusskurs: $240.00 am 2016-04-01
Kursverlauf der Aktie von Aeglea BioTherapeutics, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH